Similar articles for PMID: 36041878

Year	Number of Results
1987	1
1988	1
1993	1
1999	1
2000	1
2001	2
2002	1
2003	1
2004	5
2005	8
2006	4
2007	12
2008	1
2009	5
2010	6
2011	4
2012	5
2013	5
2014	3
2015	7
2016	11
2017	7
2018	4
2019	5
2020	5
2021	2
2022	3
2023	2
2024	0

1

Posttreatment Exposure Rates for ⁹⁰Y-Microsphere Patients: A Comparison of Products.

Blum S, Silvestrini E, Weinstein J, Greben C. Blum S, et al. J Nucl Med Technol. 2023 Mar;51(1):60-62. doi: 10.2967/jnmt.122.264335. Epub 2022 Aug 30. J Nucl Med Technol. 2023. PMID: 36041878 Free article.

2

Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.

Allison C. Allison C. Issues Emerg Health Technol. 2007 Sep;(102):1-6. Issues Emerg Health Technol. 2007. PMID: 17824141

3

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Walton M, et al. Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480. Health Technol Assess. 2020. PMID: 33001024 Free PMC article.

4

90Sr content in 90Y-labeled SIR-spheres and Zevalin.

Metyko J, Erwin W, Poston J Jr, Jimenez S. Metyko J, et al. Health Phys. 2014 Nov;107(5 Suppl 3):S177-80. doi: 10.1097/HP.0000000000000171. Health Phys. 2014. PMID: 25272027

5

Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management.

Metyko J, Williford JM, Erwin W, Poston J Jr, Jimenez S. Metyko J, et al. Health Phys. 2012 Nov;103(5 Suppl 3):S204-8. doi: 10.1097/HP.0b013e31826566f0. Health Phys. 2012. PMID: 23026974

6

Comparison of the Adverse Event Profile of TheraSphere^® with SIR-Spheres^® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review.

Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S, Ebrahim S, Mills E, Lewandowski RJ, Salem R. Kallini JR, et al. Cardiovasc Intervent Radiol. 2017 Jul;40(7):1033-1043. doi: 10.1007/s00270-017-1594-4. Epub 2017 Feb 28. Cardiovasc Intervent Radiol. 2017. PMID: 28246879 Review.

7

Development of activity standard for 90 Y microspheres.

Mo L, Avci B, James D, Simpson B, Van Wyngaardt WM, Cessna JT, Baldock C; Australian Nuclear Science Organization. Mo L, et al. Appl Radiat Isot. 2005 Aug;63(2):193-9. doi: 10.1016/j.apradiso.2005.02.002. Epub 2005 Apr 21. Appl Radiat Isot. 2005. PMID: 15963429

8

PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization.

Martí-Climent JM, Prieto E, Elosúa C, Rodríguez-Fraile M, Domínguez-Prado I, Vigil C, García-Velloso MJ, Arbizu J, Peñuelas I, Richter JA. Martí-Climent JM, et al. Med Phys. 2014 Sep;41(9):092503. doi: 10.1118/1.4892383. Med Phys. 2014. PMID: 25186412

9

Y-90 microsphere therapy: prevention of adverse events.

Schultz CC, Campbell J, Bakalyar D, Beauvais M, Feng W, Savin M. Schultz CC, et al. Cancer Biother Radiopharm. 2009 Aug;24(4):427-33. doi: 10.1089/cbr.2008.0595. Cancer Biother Radiopharm. 2009. PMID: 19694577

10

Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy.

Jha AK, Mithun S, Purandare NC, Shah SA, Agrawal A, Kulkarni SS, Shetty N, Rangarajan V. Jha AK, et al. Nucl Med Commun. 2016 Sep;37(9):917-23. doi: 10.1097/MNM.0000000000000544. Nucl Med Commun. 2016. PMID: 27182686

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year